DC vaccines developed using CD133 mRNA and MUC1 mRNA along with CTLA4 blockade have shown enhanced immune response and inhibition of tumor growth using in vivo murine TNBC models [93, 94]. The gene discussed is CTLA4; the disease is neoplasm.